Cutting-edge therapy for malignant glioma and its perspectives in the future

Yoshihiro Muragaki, Takashi Maruyama, Masahiko Tanaka, Hiroshi Iseki, Yoshikazu Okada

Research output: Contribution to journalArticle

Abstract

The prognosis of patients with malignant glioma has been improved recently, mainly due to availability of advanced intraoperative technologies for aggressive and safe tumor resection, as well as introduction of temozolomide as a highly effective drug for postoperative chemotherapy. Their use along with contemporary radiotherapy constitutes the basis of the present cutting-edge management of these tumors. Other modern therapeutic options directed on the improvement of patients' survival are currently evaluated in various clinical trials. Particularly, several kinds of immunotherapy using EGFRvIII, WT1, or autologous formalin-fixed vaccine are under investigation as well as new vectors of recombinant herpes virus and oncolytic virus for gene therapy. Additionally, various local therapies directed on the improvement of the tumor growth control have been developed, such as slow-release wafers and convection-enhanced delivery of chemotherapeutic drugs, brachytherapy, photodynamic therapy, highly focused ultrasound, etc. It can be expected that in the future combined treatment based on the synergistic biological and biophysical effects of various therapeutic modalities on the pathological tissue will be translated in further improvement of the clinical outcome of patients with malignant gliomas. Moreover, newly developed treatment approaches with the use of stem cells, seem very promising.

Original languageEnglish
Pages (from-to)892-898
Number of pages7
JournalJapanese Journal of Neurosurgery
Volume19
Issue number12
Publication statusPublished - 2010 Dec
Externally publishedYes

Fingerprint

Glioma
temozolomide
Oncolytic Virotherapy
Neoplasms
Convection
Brachytherapy
Photochemotherapy
Therapeutic Uses
Therapeutics
Pharmaceutical Preparations
Genetic Therapy
Immunotherapy
Formaldehyde
Radiotherapy
Stem Cells
Vaccines
Clinical Trials
Viruses
Technology
Drug Therapy

Keywords

  • Brain tumor
  • Local therapy
  • Novel therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Muragaki, Y., Maruyama, T., Tanaka, M., Iseki, H., & Okada, Y. (2010). Cutting-edge therapy for malignant glioma and its perspectives in the future. Japanese Journal of Neurosurgery, 19(12), 892-898.

Cutting-edge therapy for malignant glioma and its perspectives in the future. / Muragaki, Yoshihiro; Maruyama, Takashi; Tanaka, Masahiko; Iseki, Hiroshi; Okada, Yoshikazu.

In: Japanese Journal of Neurosurgery, Vol. 19, No. 12, 12.2010, p. 892-898.

Research output: Contribution to journalArticle

Muragaki, Y, Maruyama, T, Tanaka, M, Iseki, H & Okada, Y 2010, 'Cutting-edge therapy for malignant glioma and its perspectives in the future', Japanese Journal of Neurosurgery, vol. 19, no. 12, pp. 892-898.
Muragaki Y, Maruyama T, Tanaka M, Iseki H, Okada Y. Cutting-edge therapy for malignant glioma and its perspectives in the future. Japanese Journal of Neurosurgery. 2010 Dec;19(12):892-898.
Muragaki, Yoshihiro ; Maruyama, Takashi ; Tanaka, Masahiko ; Iseki, Hiroshi ; Okada, Yoshikazu. / Cutting-edge therapy for malignant glioma and its perspectives in the future. In: Japanese Journal of Neurosurgery. 2010 ; Vol. 19, No. 12. pp. 892-898.
@article{7ce5869bda9c4e2cabcd78066156d9c9,
title = "Cutting-edge therapy for malignant glioma and its perspectives in the future",
abstract = "The prognosis of patients with malignant glioma has been improved recently, mainly due to availability of advanced intraoperative technologies for aggressive and safe tumor resection, as well as introduction of temozolomide as a highly effective drug for postoperative chemotherapy. Their use along with contemporary radiotherapy constitutes the basis of the present cutting-edge management of these tumors. Other modern therapeutic options directed on the improvement of patients' survival are currently evaluated in various clinical trials. Particularly, several kinds of immunotherapy using EGFRvIII, WT1, or autologous formalin-fixed vaccine are under investigation as well as new vectors of recombinant herpes virus and oncolytic virus for gene therapy. Additionally, various local therapies directed on the improvement of the tumor growth control have been developed, such as slow-release wafers and convection-enhanced delivery of chemotherapeutic drugs, brachytherapy, photodynamic therapy, highly focused ultrasound, etc. It can be expected that in the future combined treatment based on the synergistic biological and biophysical effects of various therapeutic modalities on the pathological tissue will be translated in further improvement of the clinical outcome of patients with malignant gliomas. Moreover, newly developed treatment approaches with the use of stem cells, seem very promising.",
keywords = "Brain tumor, Local therapy, Novel therapeutics",
author = "Yoshihiro Muragaki and Takashi Maruyama and Masahiko Tanaka and Hiroshi Iseki and Yoshikazu Okada",
year = "2010",
month = "12",
language = "English",
volume = "19",
pages = "892--898",
journal = "Japanese Journal of Neurosurgery",
issn = "0917-950X",
publisher = "Japanese Congress of Neurological Surgeons",
number = "12",

}

TY - JOUR

T1 - Cutting-edge therapy for malignant glioma and its perspectives in the future

AU - Muragaki, Yoshihiro

AU - Maruyama, Takashi

AU - Tanaka, Masahiko

AU - Iseki, Hiroshi

AU - Okada, Yoshikazu

PY - 2010/12

Y1 - 2010/12

N2 - The prognosis of patients with malignant glioma has been improved recently, mainly due to availability of advanced intraoperative technologies for aggressive and safe tumor resection, as well as introduction of temozolomide as a highly effective drug for postoperative chemotherapy. Their use along with contemporary radiotherapy constitutes the basis of the present cutting-edge management of these tumors. Other modern therapeutic options directed on the improvement of patients' survival are currently evaluated in various clinical trials. Particularly, several kinds of immunotherapy using EGFRvIII, WT1, or autologous formalin-fixed vaccine are under investigation as well as new vectors of recombinant herpes virus and oncolytic virus for gene therapy. Additionally, various local therapies directed on the improvement of the tumor growth control have been developed, such as slow-release wafers and convection-enhanced delivery of chemotherapeutic drugs, brachytherapy, photodynamic therapy, highly focused ultrasound, etc. It can be expected that in the future combined treatment based on the synergistic biological and biophysical effects of various therapeutic modalities on the pathological tissue will be translated in further improvement of the clinical outcome of patients with malignant gliomas. Moreover, newly developed treatment approaches with the use of stem cells, seem very promising.

AB - The prognosis of patients with malignant glioma has been improved recently, mainly due to availability of advanced intraoperative technologies for aggressive and safe tumor resection, as well as introduction of temozolomide as a highly effective drug for postoperative chemotherapy. Their use along with contemporary radiotherapy constitutes the basis of the present cutting-edge management of these tumors. Other modern therapeutic options directed on the improvement of patients' survival are currently evaluated in various clinical trials. Particularly, several kinds of immunotherapy using EGFRvIII, WT1, or autologous formalin-fixed vaccine are under investigation as well as new vectors of recombinant herpes virus and oncolytic virus for gene therapy. Additionally, various local therapies directed on the improvement of the tumor growth control have been developed, such as slow-release wafers and convection-enhanced delivery of chemotherapeutic drugs, brachytherapy, photodynamic therapy, highly focused ultrasound, etc. It can be expected that in the future combined treatment based on the synergistic biological and biophysical effects of various therapeutic modalities on the pathological tissue will be translated in further improvement of the clinical outcome of patients with malignant gliomas. Moreover, newly developed treatment approaches with the use of stem cells, seem very promising.

KW - Brain tumor

KW - Local therapy

KW - Novel therapeutics

UR - http://www.scopus.com/inward/record.url?scp=79951783285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951783285&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79951783285

VL - 19

SP - 892

EP - 898

JO - Japanese Journal of Neurosurgery

JF - Japanese Journal of Neurosurgery

SN - 0917-950X

IS - 12

ER -